News
July 22, 2020
BlueSphere Bio Appoints Drug Development Leader Dr. Michael Geffner as Chief Medical Officer
BlueSphere Bio has appointed a veteran drug development leader, Michael Geffner, M.D., M.B.A., as the company’s first chief medical officer.
July 9, 2020
BlueSphere Bio Names Immune Oncology Pioneers to Scientific Advisory Board
Members of the scientific advisory board include Carl June, M.D., Ulrich von Andrian, M.D, Greg Delgoffe, Ph.D, and Marc Jenkins, Ph.D.
July 31, 2019
Immune Oncology Innovator BlueSphere Bio Names Veteran Biotech Leader David Apelian as CEO
With Pitt Expertise and UPMC Funding, BlueSphere’s TCXpress Platform to Develop Rapid, Personalized T-Cell Therapies for Cancer Treatment.